16 September 2026 editorial review · Trial
Repeat BCG vaccination in pediatric T1D: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Corrected 150 from actual enrollment to registry estimate; active-not-recruiting status does not confirm final recruited count. Rewrote current-status prose and substantive eligibility; no pediatric efficacy results.
Registry: NCT05180591; ACTIVE_NOT_RECRUITING; updated 2026-06-26; enrollment 150 (ESTIMATED); results not posted.
Endpoint comparison: Change in HbA1c values (1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, and 5 years after initial BCG/placebo injection).
Sources for this record: NCT05180591: Repeat BCG vaccination in pediatric T1D (registry); NCT02081326: Repeat BCG vaccination in established (adult) T1D (registry).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.